Development of Subcutaneous Implants of Controlled Release Formulations of Carvedilol for Sustained Blood Pressure Reduction in Experimental Models of Hypertension
暂无分享,去创建一个
D. Chiappetta | M. Moretton | F. Bertera | C. Höcht | M. Allo | Luciano Parola | Camila Melody Boquete | Yanina Santander Pantamura
[1] D. Jain,et al. Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: Optimization and pharmacokinetic study. , 2019, International journal of biological macromolecules.
[2] K. Hosny,et al. Optimization of carvedilol solid lipid nanoparticles: An approach to control the release and enhance the oral bioavailability on rabbits , 2018, PloS one.
[3] K. Kario,et al. Blood pressure monitoring: theory and practice. European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability Teaching Course Proceedings. , 2017, Blood pressure monitoring.
[4] C. Hocht,et al. What is the Real Efficacy of Beta-Blockers for the Treatment of Essential Hypertension? , 2017, Current pharmaceutical design.
[5] D. Chiappetta,et al. Novel carvedilol paediatric nanomicelle formulation: in‐vitro characterization and in‐vivo evaluation , 2017, The Journal of pharmacy and pharmacology.
[6] D. Chiappetta,et al. Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability. , 2017, Journal of the American Society of Hypertension : JASH.
[7] Guido Grassi,et al. Evidence for a critical role of the sympathetic nervous system in hypertension. , 2016, Journal of the American Society of Hypertension : JASH.
[8] Gavin W K Wong,et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. , 2015, The Cochrane database of systematic reviews.
[9] Claus-Michael Lehr,et al. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[10] J. Flack,et al. Benefits of once-daily therapies in the treatment of hypertension , 2011, Vascular health and risk management.
[11] M. Boccia,et al. In vitro/in vivo characterization of melt-molded gabapentin-loaded poly(epsilon-caprolactone) implants for sustained release in animal studies. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[12] P. Gosse,et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials , 2007, Blood pressure monitoring.
[13] D. Brooks,et al. Antioxidant activity of carvedilol in cardiovascular disease , 2007, Journal of hypertension.
[14] D. Su,et al. Reduction of blood pressure variability: a new strategy for the treatment of hypertension. , 2005, Trends in pharmacological sciences.
[15] P. Meredith. A Chronotherapeutic Approach to Effective Blood Pressure Management , 2000, Journal of clinical hypertension.
[16] U. Jana,et al. PREPARATION AND PHYSICO-CHEMICAL CHARACTERIZATION OF CARVEDILOL-EUDRAGIT , 2018 .
[17] W. Elliott. Prevention of Cardiovascular Events With an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Tri , 2006 .
[18] F. Zacharias. Beta blockers in hypertension. , 1973, Bruxelles medical.